Introduction
B cell chronic lymphocytic leukemia (B-CLL) represents the quintessential example of a human malignancy in which the clonal excess of B cells is caused principally by defects that prevent cell turnover due to programmed cell death rather than by alterations in cell cycle regulation. In the vast majority of patients, B-CLL cells gradually accumulate not because they are dividing more rapidly than normal, but because they are surviving too long. 1 Many factors have been described to determine this abnormal extended life span due to defective apoptosis of the B-CLL cells, among them bcl-2, bax and bclxL gene over-expression, 2, 3 increased serum levels of interferon gamma, interleukin-2, 4, 6 and 13, 4 interleukin-8, 5 free iC3b (the ligand for beta 2 integrins), 6 and alpha interferon. 7 B-CLL cells have a down-regulated expression of the apoptosis-inducer CD95 (Fas), a disrupted CD95-dependent apoptotic pathway, 8 and a perturbed T cell/B cell interaction. 9 In an attempt to counteract the defective apoptosis, monoclonal antibodies (MoAbs) were used in order to trigger an intracellular antiproliferative or apoptotic signal upon binding with their cognate antigen. 10 The early immunotherapy reagents used targeted the immunoglobulin variable region (idiotype) of the malignant B cell. However, these antibody reagents proved to be impractical as treatment modalities, because being idiotype-specific, they have to be synthesized individually for each patient, and also because target idiotypes are secreted by malignant B cells and can sequester the MoAb away from the malignant cells. 11 These difficulties can be avoided by using MoAbs that recognize antigens more universally expressed on the surface of B cells. One such antigen is the surface antigen CD20, against which a humanized anti-CD20 MoAb, Rituximab (Genentech, San Francisco, CA, USA; IDEC Pharmaceuticals, San Diego, CA, USA) has been applied to B-CLL patients. 12 However, clinical trials proved only a limited activity of Rituximab in B-CLL. 13 Another target antigen is the surface molecule CD52, Campath-1H being a humanized anti-CD52 MoAb which proved to be effective in patients with B-CLL. 14 CD5 is a monomeric 67-kDa class I transmembrane glycoprotein which belongs to the receptor cysteine-rich domain family of polyanion binding receptors. The surface marker CD5, which was primary described as a T cell marker, was identified on certain B cell tumors and reported in a human leukemia study. 15 Subsequently, it was identified on a subset of normal B cells 16 designated as the B-1 subset and which is found mostly in the peritoneal and pleural cavities. 17 Therefore, it seems logical to assess the effects of anti-CD5 MoAbs in B-CLL since expression of CD5 on tumor cell surface is a hallmark of the disease, and because previous studies have shown that CD5 ligation induces apoptosis in normal B cells without affecting T cells.
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In this study, we identified a group of B-CLL patients whose cells are induced into programmed cell death by anti-CD5 MoAbs. Our findings may help correlate the clinical heterogeneity of B-CLL with the developmental stages at which B cells display different responses to various stimuli, and may provide a definition of different B-CLL subsets.
Materials and methods

Patients
The twenty-four patients (12 men and 12 women) enrolled in this study were randomly chosen at hospitals from Nagano, Yamanashi and Saitama prefectures, Japan. The mean age of the patients was 66.5 years (median 70.5, range 27 to 88 years). B-CLL was diagnosed according to standard clinical and laboratory criteria, and at the time of inclusion in our study, seven patients were in stage 0, seven patients were in stage I, two patients were in stage II, two patients were in stage III, and six patients were in stage IV according to Rai classification. 19 Other characteristics of the B-CLL patients are summarized in Table 1 .
Cell preparation and culture
After informed consent, heparinized samples of peripheral blood were obtained from each patient. Peripheral blood mononuclear cells were obtained from the interphase cell layer after Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation and washed twice in PBS. B-CLL cells were purified by negative selection executed by removal of T and NK cells using immunomagnetic anti-CD2 coated microbeads (Dynabeads M-450; Dynal, Oslo, Norway). Because anti-CD19 and anti-CD20 MoAbs were reported to influence the apoptosis phenomenon, 20,21 a positive selection using microbeads linked to these antibodies was not considered suitable. The monocytes were removed from the cell suspensions by adherence for 2 h at 37°C to a plastic surface (Costar, Cambridge, MA, USA). Control flow cytometry analysis performed on purified B-CLL cells showed that these cells comprised more than 95% CD19 + B cells (mean 97.2 ± 1.9%).
The purified B-CLL cells were cultured at the concentration of 5 × 10 5 /ml for different periods of time in six-well plates (BD Labware, Franklin Lakes, NJ, USA), in RPMI 1640 medium (Nikken BioMedical Laboratory, Kyoto, Japan) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% antibiotics (penicillin 100 IU/ml, 100 g/ml streptomycin and fungizone, from Bio-Whittaker, Walkersville, MA, USA). The plates were placed in a 5% CO 2 -95% air fully humidified atmosphere at 37°C and incubated until cell harvesting. For the surface hypercross-linking, the wells were precoated 12 h before at 4°C with 100 g goat anti-mouse IgG (PharMingen International, Tokyo, Japan). B-CLL cells were cultured in the presence of anti-CD5 MoAbs (clone L17F12, IgG 2 , from Becton Dickinson Immunocytometry Systems, San Jose, CA, USA; and clone UCHT2, IgG 2 , from PharMingen International) and/or anti-CD20 (clone L27, IgG 1 , from Becton Dickinson) at 15 g/ml, also in the presence of a corresponding subclass of control antibody (IgG 1 from Becton Dickinson, and IgG 2 from Immunotech, Coulter, Marseille, France).
Immunofluorescence antibodies and reagents
The murine MoAbs used in this study were phycoerythrin (PE)- 
Surface immunophenotype and intracellular flow cytometric analysis
Cells were extracted from their culture media after 6, 12 and 24 h, washed in PBS and stained at 4°C for 15 min with the appropriate amount of MoAb, washed again in PBS and subjected to flow cytometric analysis on a FACScan (Becton Dickinson, Mountain View, CA, USA) equipped with a 488 nm blue argon laser. On a forward scatter/side scatter (FSC/SSC) dot-plot, the cell population was electronically gated, to avoid analysis of unwanted debris. 3 × 10 4 events were analyzed each time, and results were plotted on logarithmic scales. The percentage of cells expressing an antigen on their surface was calculated using Cell Quest (Becton Dickinson). The relative level of antigen detected on the B-CLL cell surface was quantified as the mean fluorescence intensity ratio (MFIR). MFIR was calculated according to the following formula: the mean fluorescence intensity (MFI) of cells stained with a specific FITC-or PE-conjugated MoAb divided by the MFI of control cells. For intracellular staining, cells were fixed and permeabilized using the two-step IntraStain from Dako, according to the procedure recommended by the manufacturer.
Apoptosis assays
The Annexin V fluorescent assay was performed according to the manufacturer's instructions. Cells were extracted from the culture media and washed with PBS, then 10 6 cells were stained with 2 l Annexin V FITC in the incubation buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl 2 ). In order to discriminate between apoptotic cells and cells which have permeabilized their membranes (dead cells), a counterstain using 5 g/ml PI or 7-AAD was used. 3 × 10 4 events from the double-gated area (gate 1 based on FSC/SSC pattern and gate 2 for CD5 + cells) were analyzed each time, results being plotted on a Annexin V/PI logarithmic scattergram.
The DiOC 6 (3) fluorochrome assay, which reveals the disruption of the mitochondrial transmembrane potential (⌬⌿m), an early and irreversible step of ongoing lymphocyte apoptosis, was performed according to Zamzami et al. 22 10 6 cells were incubated with 40 nM DiOC 6 (3) for 15 min at 37°C, followed by flow cytometric analysis. In this assay, the apoptotic cells are identified by their decreased ⌬⌿m (DiOC 6 (3) low ). The PARP fluorescent assay was performed by fixing and permeabilizing 10 6 cells, then staining for 30 min at 4°C with 10 l of FITC-conjugated anti-PARP cleavage site (214/215) antibody.
The caspase-3 fluorescent assay was performed according to the manufacturer's indications. 10 6 cells were permeabilized and then stained for 20 min at 4°C with 20 l of the PE-conjugated anti-active caspase-3 MoAb, which recognizes active human caspase-3, as opposed to pro-caspase-3. The following flow cytometric analysis could discriminate between cells which have or not exposed the conformational epitope formed by the cleavage of the pro-caspase-3.
Statistical analysis
The paired Student's t-test was used to determine the statistical significance of the data obtained and to compare means of Leukemia two groups. The software used was StatView (Abacus Concepts, Berkeley, CA, USA). Differences were considered statistically significant for P values Ͻ0.05. The KolmogorovSmirnov statistics were used to assess the flow cytometric histograms and the statistical significance of their shifting.
Results
Induction of apoptosis by CD5 hypercross-linking with anti-CD5 MoAbs
After 24 h of culture in the presence of anti-CD5 MoAb, the determination of the apoptotic levels in the highly purified B-CLL cells revealed a significant increase of apoptosis in the cells from 10 patients, where the apoptotic levels increased more than two times compared with the control. Therefore, we divided the patients into two groups, A and B, according to the pro-apoptotic effect exerted by the anti-CD5 MoAbs ( Table 2 ). The apoptotic level in group A, determined as phosphatidylserine externalization, was 38.8 ± 11.0%, while that in group B was 9.7 ± 4.9% (P Ͻ 0.01). The spontaneous apoptotic levels were not different between the two groups: 10.4 ± 5.3% (group A) vs 10.2 ± 4.2% (group B).
As shown in Figure 1a , apoptosis, as determined by phophatidylserine exposure on the outer cellular membrane, was induced on the CD5 hypercross-linked B-CLL cells from patient group A mainly between 6 and 12 h of culture, so significant increases in apoptotic levels could be detected after 12 h of culture. However, the apoptosis-induction timing was not homogeneous, because the cells from one patient were induced into apoptosis before 6 h, and also in the cells from another patient apoptosis was induced later, between 12 and 24 h after the hypercross-linking. In the CD5 hypercrosslinked cells from patient group B, apoptosis induction did not take place at all (Figure 1b) . A second anti-CD5 MoAb used, the clone UCHT2, which recognizes a different CD5 epitope (demonstrated by blocking experiments where binding of one MoAb did not prevent binding of the other MoAb) produced results almost identical with L17F12, indicating that programmed cell death induction was not dependent on the epitope recognized by the anti-CD5 antibody. In the absence of the goat anti-mouse hypercross-linker antibody, apoptosis induction was weaker (data not shown), similar to results obtained with IgM 20 and CD20. 21 These differential apoptotic rates were repetitively reproduced, the B-CLL cells being obtained twice from the patients over a period of a few months, demonstrating that the two distinct B-CLL populations are maintaining their different proapoptotic potentials over time.
The apoptotic pathway of anti-CD5 MoAb
As shown in Figure 2a and Table 3 , experiments performed on B-CLL cells from eight group A patients after CD5 hypercrosslinking revealed increased percentages of cells having detectable levels of active caspase-3, compared with the control samples (4.6 ± 3.8% control vs 28.9 ± 6.7% in CD5 hypercross-linked cells, P Ͻ 0.01). Thus, the anti-CD5 programmed cell death induction pathway involved the activation of one essential executioner caspase, namely the caspase-3.
Poly (ADP-ribose) polymerase cleavage is considered to be one of the classic characteristics of apoptosis. PARP is a 116- kDa nuclear protein which is strongly activated by DNA strand breaks. During apoptosis, caspase-3 and -7 cleave PARP to yield an 85-kDa and a 25-kDa fragment. 23 As shown in Figure 2b and Table 3 , significant increases of the 85-kDa fragment of cleaved PARP, as a hallmark of apoptosis induction in anti-CD5 hypercross-linked B-CLL cells, were detected in the cells from eight group A patients tested (8.1 ± 4.0% control vs 34.9 ± 9.7% CD5 hypercross-linked, P Ͻ 0.01).
Another finding was that the mitochondrial transmembrane potential ⌬⌿m, which has been shown to constitute an early and irreversible step of programmed lymphocyte death, 22 was already reduced at 6 h after CD5 hypercross-linking. As shown in Figure 3 and Table 3 , using the potentiometric marker DiOC 6 (3), the percentage of cells displaying a reduced ⌬⌿m significantly increased in the CD5 hypercross-linked samples in the eight group A patients tested (14.7 ± 4.6% control vs 43.1 ± 9.5% CD5 hypercross-linked, P Ͻ 0.01). Therefore, another important step of the apoptotic pathway initiated by CD5 cross-linking seems to involve the mitochondria. Nothing significant happened with caspase-3, PARP and DiOC 6 (3) levels in the cells from the 11 group B patients tested ( Table 3 ).
The effect of anti-CD20 MoAb on B-CLL cells
Anti-CD20 antibodies have demonstrated apoptosis-inducing effects on B-CLL cells, 21 therefore we compared the activities of anti-CD5 and anti-CD20 MoAbs (clone L27). In our hands, clone L27 had a clear in vitro apoptosis-inducing effect in five of the seven patient group A cases tested. The pro-apoptotic effects of anti-CD5 and anti-CD20 MoAbs were comparable in intensity at 24 h, and the resulting percentages of apoptotic B-CLL cells were higher when the monoclonal antibodies were used together ( Figure 3) . The mean ± s.d. apoptotic levels at 24 h in the seven cases tested were 10.08 ± 6.32% (control), 37.83 ± 12.20% (anti-CD5), 29.66 ± 8.98% (anti-CD20), and 59.37 ± 11.90% (anti-CD5 + anti-CD20). Thus, it is suggested that the pro-apoptotic effects of anti-CD5 and anti-CD20 MoAbs are additive. In the B-CLL cells from patient group B, where anti-CD5 MoAbs were ineffective, anti-CD20 MoAbinduced apoptosis still appeared. Moreover, in the two cases from group A in which CD20 hypercross-linking did not produced apoptosis induction, anti-CD5 MoAb was able to do this (Figure 4) , suggesting that the mechanism of induction of programmed cell death may be different from that used by anti-CD20 MoAb.
Modulation of the apoptosis-related proteins after CD5 hypercross-linking
Members of the Bcl-2 family have been demonstrated to be directly related to apoptosis induction propensity or resistance. 24 Therefore, we examined the endogenous levels of Bcl-2, Bax and Mcl-1 protein expression in B-CLL cells after CD5 hypercross-linking with anti-CD5 MoAbs in the B-CLL cells of eight group A patients and 11 group B patients. As shown in Figure 5a , b and c, Bcl-2 and Mcl-1 protein expression suffered a significant decrease after CD5 hypercross-linking in B-CLL cells from patient group A (Bcl-2 MFIR 26.9 ± 7.7 control vs 12.5 ± 6.6 in CD5 hypercross-linked, P Ͻ 0.01, Mcl-1 MFIR 27.7 ± 7.4 control vs 11.5 ± 5.4, P Ͻ 0.01), while Bax protein expression was significantly increased (MFIR 14.9 ± 10.3 con- trol vs 29.5 ± 6.5, P Ͻ 0.01). Because a functional inducible nitric oxide synthase displaying anti-apoptotic activity was demonstrated in B-CLL and hairy cell leukemia, [25] [26] [27] we also examined iNOS expression after CD5 hypercross-linking in eight group A and 11 group B patients, and found a significant decrease of its levels in the B-CLL cells of group A patients (MFIR 10.8 ± 3.4 control vs 5.1 ± 2.0, P Ͻ 0.01), as shown in Figure 5d . Nothing significant happened with the expression of these apoptosis-related proteins in the cells from the 11 group B patients tested. 
Leukemia
Expression of activation-associated molecules following CD5 hypercross-linking
B-CLL cells from both groups A and B were analyzed to verify modulation of CD25, CD69, CD23, CD72, CD95 and CD24 surface antigens after 6 h of culture in the absence (control) or presence of anti-CD5 MoAbs. Following CD5 hypercrosslinking, only CD25 and CD69 early activation markers suffered a significant up-regulation in both groups. The average percentage of CD25-expressing cells increased to 53.7 ± 15.0% (control 27.9 ± 15.0%, P Ͻ 0.01), and the average percentage of CD69-expressing cells increased to 30.3 ± 16.3% (control 14.7 ± 11.9%, P Ͻ 0.01). Mean fluorescence intensities of CD25 and CD69 suffered a consequent increase following CD5 hypercross-linking, the CD25 and CD69 histograms being significantly shifted to the right (CD25 MFIR 32.2 ± 6.5 vs 16.7 ± 7.6 control, P Ͻ 0.05, CD69 MFIR 20.9 ± 8.4 vs 11.5 ± 5.7 control, P Ͻ 0.05). Nothing significant happened either with the percentages of CD23-, CD72-, CD95-and CD24-expressing cells, or with the mean fluorescence intensities of these surface antigens on B-CLL cells upon CD5 hypercross-linking.
Analysis of group characteristics
Statistical analysis of the clinical and biological characteristics of patient groups A and B revealed a few significant differences between them. One of the most important findings was MFIR, mean fluorescence intensity ratio; NS, statistically not significant.
Figure 3
Representative flow cytometric result for anti-CD5 and anti-CD20 hypercross-linked B-CLL cells. B-CLL cells were cultured in the presence of an isotype-matched mouse MoAb plus goat antimouseAb (a), anti-CD5 (clone L17F12) plus goat anti-mouse Ab (b), anti-CD20 (clone L27) plus goat anti-mouse Ab (c), or anti-CD5 plus anti-CD20 plus goat anti-mouse Ab (d). The typical flow cytometric histograms illustrated here were obtained by analyzing the abovenamed four populations of cells stained with the mitochondrial potential marker DiOC 6 (3). The percentages shown represent the percentages of apoptotic cells displaying a reduced mitochondrial transmembrane potential (⌬⌿m low ). FL1 = log DiOC 6 (3) .
that the B-CLL cells from patient group A had significantly higher expression of CD25 and CD23 than those from patient group B, both on percentages of CD25-and CD23-expressing cells (40.6 ± 11.7% vs 19.6 ± 9.3% for CD25, P Ͻ 0.05, and 70.4 ± 16.0% vs 48.9 ± 12.2% for CD23, P Ͻ 0.05), also on MFIR (23.9 ± 5.7 vs 12.3 ± 5.4 for CD25, P Ͻ 0.05, and 56.8 ± 16.4 vs 35.9 ± 10.2 for CD23, P Ͻ 0.05). Another significant finding was that at the same percentage of CD72 + cells (97.4 ± 2.3% group A and 97.1 ± 1.8% group B), the CD72 mean fluorescence intensity was higher on the B-CLL cells from
Figure 4
The additive effect of anti-CD5 and anti-CD20 MoAbs. B-CLL cells from seven group A patients were cultured in the absence (control samples) or presence of anti-CD5 (clone L17F12), anti-CD20 (clone L27), or anti-CD5 plus anti-CD20 MoAbs, strongly cross-linked with goat anti-mouse Ab. After 24 h the percentage of apoptotic cells in each cell population was quantified by the Annexin V FITC method, as described in Materials and methods. *Indicates P Ͻ 0.05. group B compared with group A (MFIR 7.3 ± 2.6 vs 3.7 ± 1.3, P Ͻ 0.01). At the same percentage of CD5 + CD19 + cells (91.2 ± 2.6% group A vs 90.9 ± 6.5% group B), the CD5 MFIR was significantly higher on B-CLL cells from patient group B than the CD5 MFIR of B-CLL cells from patient group A (44.0 ± 8.8 vs 35.0 ± 7.5, P Ͻ 0.05). Chromosomal analysis showed that two patients from group A had trisomy 12, but none from group B presented this abnormality. The differences between the two patient groups regarding age (64.9 ± 9.3 years group A vs 64.9 ± 15.6 years group B), WBC counts (31301 ± 19807 × 10 6 /l group A vs 30384 ± 15784 × 10 6 /l group B), lymphocyte percentages ( 82.6 ± 9.5% group A vs 77.5 ± 12.9% group B) and Rai stage (1.8 ± 1.5 group A vs 1.6 ± 1.7 group B) were under the threshold of statistical significance. 
Discussion
Our results indicating that CD5 hypercross-linking with anti-CD5 MoAbs results in programmed cell death induction in B-CLL cells from a group of patients are at variance with those of Cantor et al, 28 who described an anti-apoptotic effect of CD5 cross-linking in bovine CD5 + B cells and no effect in CD5 + B cells from animals with persistent lymphocytosis (a non-neoplastic expansion of CD5
+ B cell population induced by bovine leukemia virus). However, CD5
+ cells from persistently lymphocytotic cattle are different from human B-CLL CD5 + cells, and also human normal CD5 + cells have a different behavior compared with bovine CD5 + B cells, CD5 ligation resulting in apoptosis induction in human CD5 + B cells.
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The cross-linking of the CD5 antigen by immobilized anti-CD5 MoAbs on human T cells was shown to induce functional interleukin-2 receptors, 29 and also ligation of the CD5 molecule with anti-CD5 MoAb on human T cells was demonstrated to induce expression of the early activation antigen CD69. 30 Moreover, on B-CLL cells, Cerutti et al 31 demonstrated that anti-CD5 MoAbs significantly up-regulate ␣ (CD25), ␤, and ␥ subunits of interleukin-2 receptor, and also up-regulate the early activation antigen CD69. 31 Our results confirm these findings, the increases in percentages of activated CD25-and CD69-positive cells being complementary with the increases in surface expression.
Programmed cell death induction in B-CLL cells following cell activation resembles the activation-induced cell death (AICD) of T cells. The term AICD was initially used by Ashwell et al 32 to describe the T cell receptor-induced death of T cell hybridomas, and later extended to nontransformed human T lymphocytes 33 and splenic T cells. 34 The term AICD was also applied to describe B cell receptor-mediated apoptosis on tonsillar B cells and Burkitt lymphoma cell lines, 35 and the death of normal B cells promoted by hypercross-linking of their surface immunoglobulins. 36 The two main significant differences found between B-CLL cells from patient groups A and B were the higher percentages of CD25-and CD23-positive cells in group A and the diminished CD5 and CD72 MFIR (indicating a lower CD5 and CD72 surface expression) on cells from patient group A, compared with patient group B cells. The CD23 and CD25 antigen Leukemia distribution between groups A and B matches the previous findings of Gibson et al 37 and Barnett and Reilly, 38 that B-CLL patients with more than 50% CD23-positive cells in the peripheral blood have a significantly higher mean level of CD25-positive cells (13.8 ± 10.7% Gibson et al, 49 ± 29% Barnett and Reilly, 40.6 ± 11.9% in patient group A in our present report) than do patients with less than 50% CD23-positive cells (5.1 ± 4.2% Gibson et al, 23 ± 20% Barnett and Reilly, 19.6 ± 9.3% in patient group B in our present report). The higher activation state of the B-CLL cells from patient group A also matches some previous observations that the state of activation of malignant B-1 cells was correlated with increased apoptosis. 39 The second significant difference found by us between B-CLL cells from patient groups A and B concerned the CD5 and CD72 MFIR values, which were found to be significantly higher on cells from patient group B. CD72 has been defined as the CD5 ligand on the B cell membrane, 40 and its co-modulation with CD5 has been demonstrated. 41 One hypothesis which could explain the decreased CD72 MFIR values is that reduced surface CD72 expression follows by co-modulation CD5 MFIR decrease upon activation. Indeed, Jamin et al 42 found a decline of CD5 MFI on activated T cells which expressed CD25. Another argument sustaining this hypothesis is the finding that on B cells, the occupancy of CD72 enhances CD23 expression, 43 thus suggesting that on B-CLL cells from patient group A, the CD72 surface antigen is bound to a counterstructure and subsequently its expression is downregulated. The significance of the lower CD5 and CD72 MFIR on B-CLL cells from patient group A could indicate a higher level of CD5-CD72 interaction, with reciprocal downmodulation.
Another potential ligand identified for the CD5 antigen is the B cell surface immunoglobulin V H framework region. 44 CD5 was identified to be associated with the human B cell receptor complex 45 and to negatively regulate antigen receptor-mediated signaling. CD5 appears to regulate the early signaling events induced by B cell receptor cross-linking in B-1 cells 46 by setting a threshold which may play a role in protecting cells from antigen receptor firing either spontaneously or by weak cross-reactive interactions with antigens. In this respect, our finding of a higher activation state of B-CLL cells from patient group A suggests that indeed the CD5 hypercross-linking removes the CD5 threshold of negative regulation on B cell receptor and the activated cells become able to enter programmed cell death. It is also suggested that the regional interaction of surface immunoglobulin with CD5 could provide a autostimulatory signal necessary for B cell survival. 47 This weak but persistent survival signal provided to the B-CLL cell by the continual 'tickling' of CD5 could be disrupted by anti-CD5 MoAbs, which have a higher relative avidity, 44 thus opening the pathway of programmed cell death. Death signals triggered by B cell receptor ligation are dependent on caspase-3, 48 pointing to our finding of caspase-3 involvement in anti-CD5-induced apoptosis. Moreover, we describe the preceding step of the death pathway in anti-CD5-induced apoptosis, the disruption of the mitochondrial potential, which was also found in B cell receptor-induced apoptosis. 49 All these support the hypothesis that anti-CD5 MoAbs disrupt the weak but essential CD5-Ig framework interaction and induce programmed cell death via the same mitochondria-caspase pathway.
The findings that cells from two of our group A B-CLL patients were induced into programmed cell death by anti-CD5 but not by anti-CD20 MoAb and that anti-CD20 MoAb could induce apoptosis in the cells from group B patients suggest different apoptosis induction pathways. Signaling through CD72 was described as having an anti-apoptotic activity in B cells, the anti-immunoglobulin-induced death of mouse spleen B cells being blocked by CD72 signaling. 50 However, important differences exist between mouse spleen B cells and the human B-CLL cells we used in our experiments. One hypothesis which could explain apoptosis induction by CD5 hypercross-linking is that the anti-CD5 MoAbs could disrupt the CD5-CD72 interaction and promote cell death. If this is the case, it would explain our finding of selective apoptosis induction in the B-CLL group, in which both CD5 and CD72 had lower detectable expression, possibly because of a higher interaction level with its counterstructure. It seems possible that in our extensive cross-linking conditions, where a supraoptimal signal was delivered, both the CD5-IgV H framework region and CD5-CD72 interactions are perturbed, resulting in programmed cell death induction.
The findings that cells from two of our group A B-CLL patients were induced into programmed cell death by anti-CD5 but not by anti-CD20 MoAb and that anti-CD20 MoAb could induce apoptosis in the cells from group B patients suggest different apoptosis induction pathways and have potential therapeutic implications, considering that a subgroup of B-CLL patients may be sensitive to anti-CD5 MoAb therapy even if the anti-CD20 therapy is ineffective. Finally, regarding the additive pro-apoptotic effect of anti-CD5 and anti-CD20 MoAbs, the possibility of a combined MoAb therapy has to be further considered.
In conclusion, the results of this study demonstrate the existence of two different groups of B-CLL patients, whose leukemic cells have a different behavior after the extensive cross-linking of their surface antigen CD5 with anti-CD5 MoAbs. Cells from both patient groups suffered an early activation phenomenon, and following that, cells from patient group A entered programmed cell death. The apoptosis induction was caspase-3 and PARP-dependent and involved downregulation of the anti-apoptotic Bcl-2, Mcl-1 and iNOS proteins, together with an up-regulation of the pro-apoptotic Bax protein. Further research is necessary to define the molecular mechanisms of apoptosis induction after CD5 hypercross-linking, the specific features which distinguish the two B-CLL groups, to clarify the pathophysiological significance of this dichotomy and to establish possible B-CLL therapeutic approaches using anti-CD5 MoAbs.
